Clinical Trial Results:
            A randomized, open-label, Phase 3 study of telaprevir administered twice daily or every 8 hours in combination with pegylated interferon alfa-2a and ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C virus infection
    
| 
                 Summary 
         | 
        |
    EudraCT number  | 
        2010-021628-84 | 
    Trial protocol  | 
        BE DE GB SE AT IE PL ES IT | 
    Global completion date  | 
        
                                    28 Nov 2012
                             
         | 
    
| 
                 Paediatric regulatory details 
         | 
        |
    Is the trial part of an agreed EMA paediatric investigation plan?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 45 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
    Is the trial in scope of article 46 of Regulation (EC) No 1901/2006?  | 
        
                                        No
                                 
         | 
    
| 
                 Results information 
         | 
        |
    Results version number  | 
        v1(current) | 
    This version publication date  | 
        
                                    14 Jul 2016
                             
         | 
    
    First version publication date  | 
        
                                    14 Jul 2016
                             
         | 
    
    Other versions  | 
        |
    Summary report(s)  | 
                                VX-950-C211 (2010-021628-84)_(Telaprevir)_CT.gov Results | 
    
            Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to            Commission Guideline 2012/C 302/03
            for further information.